Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Illumina introduces pan-cancer CDx

July 2022—Illumina announced that a companion diagnostic indication has been added to its CE-marked in vitro diagnostic TruSight Oncology Comprehensive (EU) test. The CDx pan-cancer indication will allow identification of cancer patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase gene fusions including NTRK1, NTRK2, or NTRK3 and who may benefit from targeted therapy with Bayer’s Vitrakvi (larotrectinib), a genomically matched treatment.

Verichem reference materials for ammonia

June 2022—Verichem Laboratories announced the availability of a multilevel set of liquid-stable, ready-to-use clinical reference materials for the calibration and calibration verification of ammonia assays. The materials are universally compatible and can be used with a range of clinical testing systems, including from Abbott Diagnostics, Beckman Coulter, Roche Diagnostics, and Siemens Healthineers.

Proscia, Hamamatsu digital pathology collaboration

May 2022—Proscia and Hamamatsu Photonics are collaborating to accelerate the adoption of digital pathology. The agreement aims to increase the availability of the companies’ best-of-breed solution, which combines Proscia’s Concentriq platform and Hamamatsu’s NanoZoomer series of whole slide scanners, to laboratories. Users of Hamamatsu’s scanners can integrate their images and all other data into an open ecosystem centered around Concentriq. Under the agreement, customers will receive support with implementation.

CelLock cell-block prep kit

May 2022—Source Medical Products announced it is carrying CelLock, a kit that standardizes the preparation of formalin-fixed, paraffin-embedded cell blocks. Included in the kit is a proprietary product called CelLGel, which is used in concert with a proprietary filter to collect and process 99.7 percent of the initial patient specimen into the cell block. The filter is included in the cell block to provide a visual cue, the company says, to make the tasks of embedding and microtomy easier and more exacting. The cellular proteomic and genetic information within the specimen is preserved for immunohistochemical, molecular, and ancillary testing.

Siemens gets breakthrough device designation for sNfL assay

June 2022—Siemens Healthineers announced the FDA has granted breakthrough device designation for the Advia Centaur serum neurofilament light chain (sNfL) assay, developed in collaboration with Novartis Pharma. The assay quantitatively measures NfL in human serum and plasma and is intended to be used in conjunction with clinical, imaging, and laboratory findings as an aid in identifying adult patients with relapsing multiple sclerosis who are at lower risk, versus higher risk, of multiple sclerosis disease activity.

Bio-Rad introduces anti-cemiplimab antibodies

June 2022—Bio-Rad Laboratories introduced a range of antibodies specific to cemiplimab (Libtayo) that inhibit the binding of the drug to its target, human programmed death receptor-1. The ready-made antibodies are suitable for developing selective and sensitive assays for the bioanalysis and drug monitoring of cemiplimab.

Tribun Health enters pharmaceutical market

June 2022—Tribun Health announced its expansion into the pharmaceutical market with the appointment of Loic Dartois as vice president of pharma. Dartois joined Tribun Health in March and is developing commercial offerings for the pharma industry. “Digital pathology data combined with best-in-class AI models has the power to improve treatments’ responses to a better targeted population,” Dartois said in a press release. “Thanks to its growing footprint in health care institutions in Europe and North America, Tribun Health is best positioned to support the pharmaceutical industry in its precision medicine transformation using an industry-leading digital pathology platform and deploying a thought leadership AI team.”

Sysmex America to distribute Exbio antibodies

June 2020—Sysmex America has expanded its reagent portfolio by becoming a distributor of more than 450 Exbio single-color antibodies, cell stains, and buffering solutions. The company offers a comprehensive variety of analyte-specific reagent and research use only antibodies for immunophenotyping, cell staining and processing, and vitality assays, as well as for other research applications.

NxTAG gastrointestinal panel gets CE mark

June 2022—DiaSorin announced that Luminex, a DiaSorin company, CE marked its xMAP NxTAG Gastrointestinal Pathogen Panel (GPP). The new panel is a multiplex test that detects nucleic acids from 16 clinically relevant bacterial, viral, and parasitic pathogens in stool samples on the Magpix system.

MARKETPLACE

TRENDING